Buscar
Mostrando ítems 1-10 de 220
How much time is needed in clinical practice to reach a diagnosis of clinically established Parkinson's disease?
(Elsevier, 2021-11)
Introduction: The implementation of accepted clinical diagnostic criteria has improved the accuracy of a clinical diagnosis of Parkinson's disease (PD). Time frames of 3–10 years have been empirically proposed to reach a ...
Parkinson disease: Serotonin reuptake inhibitors for depression in PD
(Nature Publishing Group, 2012-07)
A recent study to investigate the safety and efficacy of serotonin reuptake inhibitors suggests that these drugs are beneficial for the treatment of depressive disorders in Parkinson disease. Whether these treatments will ...
Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease
(Springer Wien, 2018-08)
The prevalence of Parkinson´s disease, which affects millions of people worldwide, is increasing due to the aging population. In addition to the classic motor symptoms caused by the death of dopaminergic neurons, Parkinson´s ...
Hyposialorrhea as an early manifestation of Parkinson disease
(Elsevier Science, 2009-10)
We sought to determine whether hyposialorrhea is an early manifestation of Parkinson disease (PD). We measured basal and citric acid stimulated secretion of whole saliva in 20 patients with early PD. Our findings confirm ...
Reply to: ''Does Cognitive Impairment Influence Motor Speech Performance in De Novo Parkinson's Disease''
(Wiley-liss, div John Wiley & Sons Inc., 2021-12-17)
We appreciate the letter by Rusz and Tykalová as a valuable contribution to dysarthria assessments in Parkinson's disease (PD). Their report partly mirrors our methodological approach, with converging results and key ...
The pedunclopontine nucleus and Parkinson's disease
(Academic Press Inc Elsevier Science, 2019-08)
In the last decade, scientific and clinical interest in the pedunculopontine nucleus (PPN) has grown dramatically. This growth is largely a consequence of experimental work demonstrating its connection to the control of ...
Neuroprotective effects of human umbilical cord mesenchymal stromal cells in an immunocompetent animal model of Parkinson's disease
(Elsevier Science, 2012-05)
Microglial activation in the substantia nigra (SN) is a ubiquitous feature in PD which could mediate toxic effects. Human mesenchymal stromal cells (hMSCs) possess immunomodulatory properties. We evaluated whether the ...
Diagnosis and Management of Pain in Parkinson's Disease: A New Approach
(Adis Int Ltd, 2021-07)
Pain is a frequent and disabling non-motor feature of Parkinson’s disease (PD). The recently proposed PD Pain Classification System (PD-PCS) allows for an association of pain with PD to be determined before being allocated ...
A core avenue for transcultural research on dementia: on the cross-linguistic generalization of language-related effects in Alzheimer's disease and Parkinson's disease
(John Wiley & Sons Ltd, 2018-06)
Objective: Language is a key source of cross-cultural variability, which may have both subtle and major effects on neurocognition. However, this issue has been largely overlooked in two flourishing lines of research assessing ...
SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy
(Elsevier Science Inc., 2021)